Literature DB >> 36171522

Display of Streptococcus iniae α-Enolase on the Surface of Virus-Like Particles (VLPs) of Nervous Necrosis Virus (NNV) Using SpyTag/SpyCatcher.

Jeong In Yang1, Ki Hong Kim2.   

Abstract

Virus-like particle (VLP)-based vaccines are promising candidates for overcoming the safety problems of live vaccines and weak immunogenicity of subunit vaccines. VLPs can be used as a platform for the development of combined vaccines by expressing foreign antigens, and foreign antigens can be displayed on the surface of VLPs by conjugation. In the present study, to use nervous necrosis virus (NNV) VLPs as a delivery tool for Streptococcus iniae α-enolase by displaying on the VLP's surface, the split-intein (SpyTag/SpyCatcher) conjugation system was used. NNV capsid protein fused to SpyTag (Capsid-SpyTag) and S. iniae α-enolase fused to SpyCatcher (α-enolase-SpyCatcher) were recombinantly produced, then mixed in various ratios. A ratio of Capsid-SpyTag to α-enolase-SpyCatcher of 1 to 1.5 showed the highest coupling efficiency corresponding to 83-92% of coupled capsid protein dimer and 32-52% of coupled capsid protein monomer. In TEM observation, VLP of Capsid-SpyTag had a regular shape and size of about 40 nm, while VLP fused with α-enolase-SpyCatcher showed an irregular shape and size of about 40-50 nm in diameter. In preliminary immunization experiments, olive flounder (Paralichthys olivaceus) and zebrafish (Danio rerio) immunized with VLP fused with α-enolase-SpyCatcher showed the lowest cumulative mortality against S. iniae infection.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Antigen delivery; Nervous necrosis virus; SpyTag/SpyCatcher; Surface display; Virus-like particle

Year:  2022        PMID: 36171522     DOI: 10.1007/s10126-022-10166-4

Source DB:  PubMed          Journal:  Mar Biotechnol (NY)        ISSN: 1436-2228            Impact factor:   3.727


  18 in total

1.  Immune response against grouper nervous necrosis virus by vaccination of virus-like particles.

Authors:  Wangta Liu; Chi-Hsin Hsu; Chiung-Yin Chang; Hsin-Hong Chen; Chan-Shing Lin
Journal:  Vaccine       Date:  2006-06-09       Impact factor: 3.641

Review 2.  Current status and future directions of fish vaccines employing virus-like particles.

Authors:  Ki-Ho Jeong; Hyoung Jin Kim; Hong-Jin Kim
Journal:  Fish Shellfish Immunol       Date:  2020-03-01       Impact factor: 4.581

Review 3.  Progress, challenges and opportunities in fish vaccine development.

Authors:  Alexandra Adams
Journal:  Fish Shellfish Immunol       Date:  2019-04-27       Impact factor: 4.581

4.  Protective efficacy of Streptococcus iniae derived enolase against Streptococcal infection in a zebrafish model.

Authors:  Juver D Membrebe; Nam-Kyung Yoon; Minhee Hong; Jeongsoo Lee; Hongweon Lee; Kyoungmoon Park; Sin-hye Seo; Injoong Yoon; Sungsik Yoo; Yeu-Chun Kim; Jungoh Ahn
Journal:  Vet Immunol Immunopathol       Date:  2016-01-15       Impact factor: 2.046

5.  Determinants of autoantibody induction by conjugated papillomavirus virus-like particles.

Authors:  Bryce Chackerian; Petra Lenz; Douglas R Lowy; John T Schiller
Journal:  J Immunol       Date:  2002-12-01       Impact factor: 5.422

6.  Oral immunization with cell-free self-assembly virus-like particles against orange-spotted grouper nervous necrosis virus in grouper larvae, Epinephelus coioides.

Authors:  Ming-Hui Chien; Shaw-Yun Wu; Cheng-Hui Lin
Journal:  Vet Immunol Immunopathol       Date:  2018-01-31       Impact factor: 2.046

Review 7.  Virus-like particle vaccines: immunology and formulation for clinical translation.

Authors:  Braeden Donaldson; Zabeen Lateef; Greg F Walker; Sarah L Young; Vernon K Ward
Journal:  Expert Rev Vaccines       Date:  2018-09-19       Impact factor: 5.217

Review 8.  Virus-like particles: the new frontier of vaccines for animal viral infections.

Authors:  Elisa Crisci; Juan Bárcena; María Montoya
Journal:  Vet Immunol Immunopathol       Date:  2012-06-01       Impact factor: 2.046

Review 9.  Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease.

Authors:  Elaine M Castilow; Matthew R Olson; Steven M Varga
Journal:  Immunol Res       Date:  2007       Impact factor: 4.505

10.  Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease.

Authors:  Maria Florencia Delgado; Silvina Coviello; A Clara Monsalvo; Guillermina A Melendi; Johanna Zea Hernandez; Juan P Batalle; Leandro Diaz; Alfonsina Trento; Herng-Yu Chang; Wayne Mitzner; Jeffrey Ravetch; José A Melero; Pablo M Irusta; Fernando P Polack
Journal:  Nat Med       Date:  2008-12-14       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.